BR112012025264A2 - inibidor de imunoproteassoma de e´poxicetona peptídica cristalina. - Google Patents

inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.

Info

Publication number: BR112012025264A2
Authority: BR; Brazil
Prior art keywords: epoxy ketone; peptide epoxy; immunoproteasome inhibitor; crystalline peptide; crystalline
Prior art date: 2010-04-07

Application number

BR112012025264A

Other languages

English (en)

Inventor

Phiassivongsa Past

Original Assignee

Onyx Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-07

Filing date

2011-04-06

Publication date

2019-09-24

2011-04-06 Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc

2019-09-24 Publication of BR112012025264A2 publication Critical patent/BR112012025264A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Epidemiology (AREA)

BR112012025264A 2010-04-07 2011-04-06 inibidor de imunoproteassoma de e´poxicetona peptídica cristalina. BR112012025264A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32157710P	2010-04-07	2010-04-07
PCT/US2011/031436 WO2011136905A2 (en)	2010-04-07	2011-04-06	Crystalline peptide epoxyketone immunoproteasome inhibitor

Publications (1)

Publication Number	Publication Date
BR112012025264A2 true BR112012025264A2 (pt)	2019-09-24

Family

ID=44862104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112012025264A BR112012025264A2 (pt)	2010-04-07	2011-04-06	inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.

Country Status (15)

Country	Link
US (1)	US8697646B2 (pt)
EP (1)	EP2555621A4 (pt)
JP (1)	JP2013525282A (pt)
KR (1)	KR20130094185A (pt)
CN (1)	CN102946729B (pt)
AU (1)	AU2011245630B2 (pt)
BR (1)	BR112012025264A2 (pt)
CA (1)	CA2795559A1 (pt)
CO (1)	CO6630130A2 (pt)
IL (1)	IL222330A0 (pt)
MX (1)	MX2012011604A (pt)
NZ (1)	NZ602872A (pt)
RU (1)	RU2012147246A (pt)
SG (1)	SG185359A1 (pt)
WO (1)	WO2011136905A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ568068A (en)	2005-11-09	2011-10-28	Proteolix Inc	Compounds for enzyme inhibition
SI2041158T1 (sl)	2006-06-19	2013-09-30	Onyx Therapeutics, Inc.	Peptidni epoksiketoni za inhibicijo proteasomov
AU2008307510A1 (en)	2007-10-04	2009-04-09	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US20110236428A1 (en) *	2008-10-21	2011-09-29	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en)	2010-03-01	2016-06-07	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
TW201414751A (zh)	2012-07-09	2014-04-16	歐尼克斯治療公司	肽環氧酮蛋白酶抑制劑之前驅藥物
HK1211947A1 (en)	2012-08-14	2016-06-03	Trillium Therapeutics Inc.	Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
TR201816372T4 (tr)	2014-07-14	2018-11-21	Centrax Int Inc	Enzim inhibisyonu için etoksiketon bileşikleri.
ES2944958T3 (es)	2016-06-29	2023-06-27	Kezar Life Sciences	Sales cristalinas de inhibidor del inmunoproteasoma de epoxicetona peptídico
WO2018005781A1 (en)	2016-06-29	2018-01-04	Kezar Life Sciences	Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4733665C2 (en)	1985-11-07	2002-01-29	Expandable Grafts Partnership	Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en)	1988-01-19	1992-08-04	Children's Medical Center Corporation	Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en)	1989-04-23	1995-08-15	The Trustees Of The University Of Pennsylvania	Substituted cyclodextrin sulfates and their uses as growth modulating agents
JP2775047B2 (ja) *	1989-05-29	1998-07-09	寶酒造株式会社	塩酸デオキシスパガリンのα型結晶及びその製造方法
US5071957A (en)	1989-08-04	1991-12-10	Bristol-Myers Company	Antibiotic BU-4061T
US4990448A (en)	1989-08-04	1991-02-05	Bristol-Myers Company	Bu-4061T
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5340736A (en)	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en)	1993-01-04	1993-03-03	Wellcome Found	Endothelin converting enzyme inhibitors
US6660268B1 (en)	1994-03-18	2003-12-09	The President And Fellows Of Harvard College	Proteasome regulation of NF-KB activity
US6506876B1 (en)	1994-10-11	2003-01-14	G.D. Searle & Co.	LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6083903A (en)	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
DE19505263A1 (de)	1995-02-16	1996-08-22	Consortium Elektrochem Ind	Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US6335358B1 (en)	1995-04-12	2002-01-01	President And Fellows Of Harvard College	Lactacystin analogs
DE19531464A1 (de) *	1995-08-26	1997-02-27	Merck Patent Gmbh	N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
WO1997046526A1 (en) *	1996-06-07	1997-12-11	Eisai Co., Ltd.	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US6150415A (en)	1996-08-13	2000-11-21	The Regents Of The University Of California	Epoxide hydrolase complexes and methods therewith
EP2409985A3 (en)	1996-10-18	2013-05-01	Vertex Pharmaceuticals Incorporated	Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
SI0932617T1 (en)	1996-10-18	2002-06-30	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6046177A (en)	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en)	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2210769T3 (es)	1997-06-13	2004-07-01	Cydex Inc.	Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6133308A (en)	1997-08-15	2000-10-17	Millennium Pharmaceuticals, Inc.	Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6075150A (en)	1998-01-26	2000-06-13	Cv Therapeutics, Inc.	α-ketoamide inhibitors of 20S proteasome
US6099851A (en)	1998-06-02	2000-08-08	Weisman; Kenneth M.	Therapeutic uses of leuprolide acetate
US6462019B1 (en)	1998-07-10	2002-10-08	Osteoscreen, Inc.	Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en)	1998-07-10	2005-06-07	Osteoscreen, Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en)	1998-07-10	2005-01-04	Osteoscreen Inc.	Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en)	1998-08-07	2001-03-20	Universtiy Of Kansas	Water soluble prodrugs of hindered alcohols
KR20010080267A (ko)	1998-10-20	2001-08-22	밀레니엄 파머슈티컬스 인코퍼레이티드	프로테아솜 억제제 약물 작용을 모니터링하는 방법
US6492333B1 (en)	1999-04-09	2002-12-10	Osteoscreen, Inc.	Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en)	1999-05-12	2004-12-14	Yale University	Enzyme inhibition
EP2305291A1 (de)	2000-10-12	2011-04-06	ViroLogik GmbH	Verwendung von Proteasome Hemmern zur Behandlung von HIV Infektionen
CA2435146C (en)	2001-01-25	2011-03-29	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Formulation of boronic acid compounds
MXPA03010634A (es)	2001-05-21	2004-03-09	Alcon Inc	Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
EP1463719A2 (en)	2002-01-08	2004-10-06	Eisai Co., Ltd	Eponemycin and epoxomicin analogs and uses thereof
US20040116329A1 (en)	2002-01-29	2004-06-17	Epstein Stephen E.	Inhibition of proteasomes to prevent restenosis
EP1496916A2 (en)	2002-04-09	2005-01-19	Greenville Hospital System	Metastasis modulating activity of highly sulfated oligosaccharides
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20030224469A1 (en)	2002-06-03	2003-12-04	Buchholz Tonia J.	Methods and kits for assays utilizing fluorescence polarization
AU2003249682A1 (en)	2002-06-03	2003-12-19	Als Therapy Development Foundation	Treatment of neurodegenerative diseases using proteasome modulators
WO2004010937A2 (en)	2002-07-26	2004-02-05	Advanced Research & Technology Institute At Indiana University	Method of treating cancer
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
TW200418791A (en)	2003-01-23	2004-10-01	Bristol Myers Squibb Co	Pharmaceutical compositions for inhibiting proteasome
DE602004032340D1 (de)	2003-06-10	2011-06-01	J David Gladstone Inst San Francisco	Verfahren zur behandlung von lentivirusinfektionen
US7012063B2 (en)	2003-06-13	2006-03-14	Children's Medical Center Corporation	Reducing axon degeneration with proteasome inhibitors
GB0400804D0 (en)	2004-01-14	2004-02-18	Innoscience Technology Bv	Pharmaceutical compositions
US7232818B2 (en)	2004-04-15	2007-06-19	Proteolix, Inc.	Compounds for enzyme inhibition
AU2005238445B2 (en)	2004-04-15	2012-05-03	Onyx Therapeutics, Inc.	Compounds for enzyme inhibition
US8198270B2 (en)	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
PL2030981T3 (pl)	2004-05-10	2014-12-31	Onyx Therapeutics Inc	Związki do enzymatycznej inhibicji proteasomu
AU2005243140A1 (en)	2004-05-10	2005-11-24	Proteolix, Inc.	Synthesis of amino acid keto-epoxides
ES2359004T3 (es) *	2004-08-06	2011-05-17	Onyx Therapeutics, Inc.	Compuestos para inhibición enzimática de proteasoma.
EP1805208A2 (en)	2004-10-20	2007-07-11	Proteolix, Inc.	Labeled compounds for proteasome inhibition
DE602005026556D1 (de)	2004-12-07	2011-04-07	Proteolix Inc	Zusammensetzung zur proteasomhemmung
US7589066B2 (en)	2005-03-11	2009-09-15	The University Of North Carolina At Chapel Hill	Potent and specific immunoproteasome inhibitors
NZ568068A (en)	2005-11-09	2011-10-28	Proteolix Inc	Compounds for enzyme inhibition
US20070207950A1 (en)	2005-12-21	2007-09-06	Duke University	Methods and compositions for regulating HDAC6 activity
WO2007122686A1 (ja) *	2006-04-14	2007-11-01	Eisai R & D Management Co., Ltd.	ベンズイミダゾール化合物
DE102006026464A1 (de)	2006-06-01	2007-12-06	Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma	Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
SI2041158T1 (sl) *	2006-06-19	2013-09-30	Onyx Therapeutics, Inc.	Peptidni epoksiketoni za inhibicijo proteasomov
US7442830B1 (en)	2007-08-06	2008-10-28	Millenium Pharmaceuticals, Inc.	Proteasome inhibitors
AU2008307510A1 (en) *	2007-10-04	2009-04-09	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7838673B2 (en)	2007-10-16	2010-11-23	Millennium Pharmaceuticals, Inc.	Proteasome inhibitors
US20110236428A1 (en)	2008-10-21	2011-09-29	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en)	2010-03-01	2016-06-07	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition

2011
- 2011-04-06 AU AU2011245630A patent/AU2011245630B2/en not_active Ceased
- 2011-04-06 WO PCT/US2011/031436 patent/WO2011136905A2/en active Application Filing
- 2011-04-06 CA CA2795559A patent/CA2795559A1/en not_active Abandoned
- 2011-04-06 CN CN201180022014.8A patent/CN102946729B/zh not_active Expired - Fee Related
- 2011-04-06 RU RU2012147246/04A patent/RU2012147246A/ru not_active Application Discontinuation
- 2011-04-06 NZ NZ602872A patent/NZ602872A/en not_active IP Right Cessation
- 2011-04-06 JP JP2013503915A patent/JP2013525282A/ja active Pending
- 2011-04-06 US US13/639,087 patent/US8697646B2/en not_active Expired - Fee Related
- 2011-04-06 BR BR112012025264A patent/BR112012025264A2/pt not_active IP Right Cessation
- 2011-04-06 EP EP11775425.9A patent/EP2555621A4/en not_active Withdrawn
- 2011-04-06 KR KR1020127029055A patent/KR20130094185A/ko not_active Withdrawn
- 2011-04-06 MX MX2012011604A patent/MX2012011604A/es not_active Application Discontinuation
- 2011-04-06 SG SG2012073938A patent/SG185359A1/en unknown
2012
- 2012-10-05 CO CO12175456A patent/CO6630130A2/es not_active Application Discontinuation
- 2012-10-09 IL IL222330A patent/IL222330A0/en unknown

Also Published As

Publication number	Publication date
RU2012147246A (ru)	2014-05-20
IL222330A0 (en)	2012-12-31
US8697646B2 (en)	2014-04-15
US20130065827A1 (en)	2013-03-14
CN102946729A (zh)	2013-02-27
WO2011136905A3 (en)	2012-01-19
CA2795559A1 (en)	2011-11-03
CO6630130A2 (es)	2013-03-01
WO2011136905A2 (en)	2011-11-03
KR20130094185A (ko)	2013-08-23
CN102946729B (zh)	2014-11-05
EP2555621A2 (en)	2013-02-13
NZ602872A (en)	2014-05-30
SG185359A1 (en)	2012-12-28
AU2011245630A1 (en)	2012-11-01
JP2013525282A (ja)	2013-06-20
EP2555621A4 (en)	2014-07-02
MX2012011604A (es)	2013-02-27
AU2011245630B2 (en)	2014-07-03

Publication	Publication Date	Title
BR112012025264A2 (pt)	2019-09-24	inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
BRPI1009369A2 (pt)	2016-10-11	inibidores de protease da classe tripeptídeo epóxi cetona cristalinos
SMT201500271B (it)	2016-01-08	Inibitori di neprilisina
CR20120576A (es)	2013-03-04	Inhibidores de pirazolil quinazolina cinasa
DOP2012000224A (es)	2013-01-31	Compuesto heterociclico
DE102010040438A8 (de)	2014-02-06	Radarvorrichtung
BR112013025761A2 (pt)	2018-05-29	inibidores de hsp90
PT2626350E (pt)	2015-08-03	Composto de ciclopropano
EP2617715A4 (en)	2014-02-26	GLYCINTRANSPORTERHEMMER
DE112010004316A5 (de)	2013-01-03	Schraubvorrichtung
BRPI1010661A2 (pt)	2016-03-15	peptídeo
BR112012026803A2 (pt)	2016-07-12	composto
ES1074161Y (es)	2011-06-24	Lavabo
EP2482315A4 (en)	2013-08-28	SEMICONDUCTOR COMPONENT
ITTO20110489A1 (it)	2011-12-09	Dispositivo di innesto.
DE112010005804A5 (de)	2013-05-16	Transponder
IT1397128B1 (it)	2013-01-04	Dispositivo di tenuta per granitori.
BR112013002589A2 (pt)	2019-09-24	valsatana altamente cristalina
DK2623492T3 (da)	2014-08-11	Cyclohexanderivatforbindelse
BR112013009679A2 (pt)	2016-07-12	peptídeo
FI20106100A0 (fi)	2010-10-25	Alusta
IT1395794B1 (it)	2012-10-19	Elemento di rivestimento.
IT1400535B1 (it)	2013-06-11	Meccanismo di graduazione per spoletta
DE102010013460A8 (de)	2011-11-24	Farbkasten
IT1401437B1 (it)	2013-07-26	Collarino di serraggio.

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.